The purpose of this study is to see if a new diagnostic research agent named 68Ga-RM2 can show prostate cancer on a PET/CT scan. 68Ga-RM2 stands for Galium-68 labeled DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2. This study is being done because there are unmet medical needs to improve the current ways of detecting prostate cancers before surgery.
Age ≥18 years Biopsy proven adenocarcinoma of the prostate Patients with low-risk, intermediate-risk and high-risk tumors according to NCCN guidelines (2.2014) will be included Planned radical prostatectomy at MSKCC Multiparametric MRI of the pelvis (performed or planned) as routine care
Exclusion Criteria:
Patients meeting any of the following exclusion criteria will not be eligible for study entry:
Hematologic
Platelets <75K/mcL ANC <1.0 K/mcL
Hepatic laboratory values
Bilirubin >2.0 x ULN (institutional upper limits of normal) AST/ALT >2.5 x ULN
Renal laboratory values
o Creatinine > 2.0 x ULN
Claustrophobia interfering with MRI and PET/CT imaging Prior pelvic radiation Prior androgen deprivation therapy Patients deemed not surgical candidates due to prohibitive co-morbidities
